Last updated: May 21, 2026
Executive summary: Quizartinib dihydrochloride (AC220; an oral FLT3 inhibitor) is in late-stage development and commercialization planning tied to FLT3-mutated acute myeloid leukemia (AML). In the US, the drug’s FDA status is centered on the treatment of relapsed or refractory (R/R) FLT3-mutated AML after prior therapy, with further expansion possible via ongoing or planned registrational studies in earlier lines and combination regimens. Commercial upside depends on (1) conversion from accelerated/conditional pathways into durable label coverage, (2) uptake versus competing FLT3 inhibitors (gilteritinib, crenolanib where used, midostaurin earlier-line strategy, and emerging next-generation FLT3 assets), and (3) survival and response durability data versus gilteritinib benchmark outcomes. Patent and exclusivity calendars will be decisive for US generic or biosimilar risk, though direct timing requires Orange Book and patent-list verification per NDA/BLA and can’t be completed from the provided scope.
Quizartinib dihydrochloride (AC220): What is the current clinical trials status and how do the key studies read?
Bottom line: Quizartinib’s clinical narrative is anchored to FLT3-mutated AML where unmet need is highest in R/R settings. The most market-relevant trial readouts are those that clarify overall survival (OS), event-free survival (EFS), and the durability of complete remission (CR/CRh) relative to standard-of-care, especially gilteritinib.
Which indications are most likely to drive label expansion?
Core, market-relevant indication clusters:
- R/R FLT3-mutated AML: Current or near-term label focus.
- Frontline FLT3-mutated AML: Trials in newly diagnosed AML often pursue combination strategies or post-remission consolidation approaches.
- Combination regimens: FLT3 inhibitors combined with hypomethylating agents (HMAs), cytotoxic chemotherapy, or venetoclax-based backbones can target broader patient populations and deepen responses.
What endpoints matter for commercialization?
For payer and prescriber adoption in AML:
- OS and durability of response are the primary determinants of adoption in R/R AML.
- CR/CRh rate and time-to-response affect early uptake.
- MRD negativity rates can influence consolidation strategy adoption if shown consistently.
Trial readout themes investors focus on
- Whether benefit is restricted to ITD versus TKD subsets.
- Whether resistance mechanisms emerge with consistent patterns that change next-generation sequencing strategy.
- Whether combination arms increase toxicity and offset OS benefit.
Which FLT3 mutations and patient subgroups matter most for quizartinib adoption?
Bottom line: FLT3 mutation subtype and disease biology drive response and switching behavior. Quizartinib’s positioning is strongest where clinicians see meaningful activity with manageable tolerability.
ITD vs TKD: does response differ?
Clinician adoption hinges on:
- Whether response is consistently higher in FLT3-ITD than FLT3-TKD.
- Whether activity exists in previously treated populations that have had FLT3 exposure through prior lines.
Prior FLT3 inhibitor exposure and line-of-therapy
Market behavior depends on:
- Sensitivity after failure of other FLT3 inhibitors (cross-resistance signals).
- Whether quizartinib becomes a preferred sequencing option post-gilteritinib or only retains value as a first FLT3 inhibitor.
Quizartinib dihydrochloride market analysis: Who are the competitors and what is the uptake battleground?
Bottom line: The competitive set is dominated by gilteritinib in R/R FLT3-mutated AML. Quizartinib’s value proposition is judged against gilteritinib on survival, response durability, safety profile, and ease of use, plus head-to-head or indirect comparisons where available.
Main comparators
- Gilteritinib (R/R FLT3-mutated AML standard comparator in the US market)
- Other FLT3-directed agents in niche roles or other geographies/lines of therapy
- Non-FLT3 standards that compete for sequencing time, including venetoclax-based regimens and HMAs
How does quizartinib’s differentiation get priced into adoption?
Prescriber adoption accelerates when quizartinib offers:
- Higher or more durable CR/CRh rates with acceptable toxicity.
- Clinically meaningful OS improvement or at least comparable OS with improved quality-of-life/tolerability.
- Clear post-progression options and a predictable resistance story.
When does quizartinib gain or lose exclusivity, and what does that mean for generic entry risks?
Bottom line: A generic entry risk model requires exact US patent and Orange Book mapping for the specific NDA listing tied to quizartinib dihydrochloride. That mapping is not provided in the prompt, so exclusivity and patent-expiration-based launch calendars cannot be computed here.
What drives US exclusivity and patent barriers
- NDA patent listings (composition, formulation, method-of-use, and process)
- Patent term adjustments (PTA) and patent term extensions (PTE)
- Pediatric exclusivity and any exclusivity stacking
- Listing changes (continuations, supplements) that alter the later filing landscape
What is the Orange Book status of quizartinib dihydrochloride and which patents protect it?
Bottom line: Orange Book status is listing-specific and requires the exact NDA number and the active ingredient/strength match. Without those data in the provided input, a compliant patent list and claim-scope analysis cannot be produced.
What you typically see in FLT3 inhibitor estates
Expect clusters in:
- Active ingredient or salts: composition of matter and salt-form patents
- Formulations: crystalline form, particle size, polymorphs, solid-state stability, excipient blends
- Methods of use: treatment of FLT3-mutated AML and specific line-of-therapy claims
- Manufacturing/process: synthesis steps and purification parameters
Which patent litigation and Paragraph IV challenges could affect quizartinib’s future?
Bottom line: Litigation risk is specific to the number of ANDA filings, timing of Paragraph IV certifications, and settlement outcomes. No litigation dataset is provided in the prompt, so an accurate forecast of future challenges cannot be generated here.
What to monitor
- ANDA/Paragraph IV docketing for quizartinib
- Settlement terms affecting launch timing, shared exclusivity, and non-infringement carve-outs
- Motions for preliminary injunction and claim-construction outcomes
Quizartinib dihydrochloride vs gilteritinib: How do the clinical and commercial trajectories compare?
Bottom line: Commercial performance in R/R FLT3-mutated AML typically tracks OS credibility and durability of responses that hold up in real-world settings. In the absence of trial-by-trial numeric readouts in the provided prompt, a quantitative comparison cannot be completed in a way that would be actionable for patent and launch risk modeling.
Key comparison axes
- OS benefit magnitude and durability
- Response rate breakdown (CR/CRh) and time-to-event curves
- Safety profile drivers affecting dose intensity and discontinuation
- Real-world sequencing patterns and post-FLT3-inhibitor sensitivity
What market size and revenue projection is plausible for quizartinib in FLT3-mutated AML?
Bottom line: Market sizing and revenue forecasts require anchored assumptions on: labeled addressable population, treatment duration, market share vs comparator, and price net of rebates. The prompt provides no dataset for pricing, patient incidence, or trial outcomes, so a numeric forecast would not be complete or reliable.
Commercial model structure (what determines the shape of the curve)
A defensible forecast is built from:
- FLT3-mutated AML incidence among newly diagnosed and R/R populations
- Eligible lines based on label
- Uptake penetration and switching behavior from gilteritinib
- Treatment duration distributions tied to discontinuation rates and survival
- WAC-to-net conversion and payer constraints for AML specialty drugs
How strong is the patent estate for quizartinib and which patent types are most defensible?
Bottom line: Patent strength depends on the actual claim sets, prosecution history, and litigation or administrative outcomes. The prompt provides no patent list, so an estate-strength scoring cannot be calculated.
Typical FLT3 inhibitor defensibility profile
- Composition claims for the active moiety and salt forms often provide the most durable legal coverage.
- Method-of-use claims can be strong if tied to robust clinical evidence but face more design-around and labeling-claim narrowing risk.
- Formulation and solid-state claims can be strong if polymorph/crystal form exclusivity is tightly defined and reproducible, but validity can be sensitive to prior-art overlaps.
What formulations are protected for quizartinib dihydrochloride (and how do those affect manufacturing/IP barriers)?
Bottom line: Formulation protection is product- and patent-specific and must be derived from Orange Book and patent documents. Without those documents in the provided input, formulation-protection mapping cannot be completed.
Manufacturing barriers that often matter
- Solid-state form control (polymorph/crystal form)
- Particle size and dissolution rate specifications
- Stability-driven excipient or coating constraints
- Process parameter restrictions that affect how generics reproduce quality attributes
Biosimilar risk: Is quizartinib subject to biologic competition timelines?
Bottom line: Quizartinib dihydrochloride is a small-molecule drug. Biosimilar frameworks and biologics exclusivity regimes are not applicable; the relevant competitive threat is generic small-molecule entry after patent and exclusivity expiration plus any litigation outcomes.
Key Takeaways
- Quizartinib’s commercialization outlook is driven by late-stage clinical proof in FLT3-mutated AML, with the R/R setting as the core adoption battleground.
- Competitive uptake will be benchmarked against gilteritinib on survival and durability, with additional pressure from combination regimens and sequencing strategy.
- Patent and exclusivity-driven generic risk is the key swing factor for launch threats; however, a precise timeline and estate map cannot be generated from the prompt alone.
- A credible revenue projection requires label-specific population, pricing/net assumptions, and trial durability endpoints, none of which are provided here.
FAQs
- What clinical endpoints most influence FLT3 inhibitor adoption in relapsed AML?
- How do FLT3-ITD versus FLT3-TKD mutation profiles change response to quizartinib?
- What is the competitive positioning of quizartinib relative to gilteritinib in treatment sequencing?
- What patent claim categories typically survive challenges for small-molecule AML kinase inhibitors?
- How do combination regimens (HMA and venetoclax) affect the commercial ceiling for FLT3 inhibitors?
References
- (No sources were provided in the prompt for clinical-trial particulars, FDA label status, Orange Book listings, or patent/litigation records.)
